J.W. Cole Advisors Inc. Sells 6,407 Shares of Amgen Inc. $AMGN

J.W. Cole Advisors Inc. cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 27.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,789 shares of the medical research company’s stock after selling 6,407 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Amgen were worth $5,495,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares in the last quarter. Capital International Investors raised its position in Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock valued at $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors raised its position in Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after buying an additional 1,935,876 shares during the last quarter. Geode Capital Management LLC raised its position in Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after buying an additional 1,035,779 shares during the last quarter. Finally, Norges Bank purchased a new stake in Amgen in the 4th quarter valued at $2,164,162,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 1.2%

Shares of NASDAQ:AMGN opened at $349.58 on Friday. The company has a market capitalization of $188.67 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 3.47 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The business has a fifty day moving average price of $341.35 and a two-hundred day moving average price of $345.47. Amgen Inc. has a 1 year low of $267.83 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of analyst reports. Morgan Stanley set a $332.00 price target on Amgen in a research report on Friday, May 1st. Royal Bank Of Canada increased their price target on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Mizuho increased their price target on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Finally, Piper Sandler lowered their price target on Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and an average price target of $353.81.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.85% of the stock is owned by company insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.